{"id":"https://openalex.org/W2942237342","doi":null,"title":"Atezolizumab (Tecentriq\u00ae) with nab-paclitaxel (Abraxane\u00ae) for the treatment of advanced triple-negative breast cancer (aTNBC)","display_name":"Atezolizumab (Tecentriq\u00ae) with nab-paclitaxel (Abraxane\u00ae) for the treatment of advanced triple-negative breast cancer (aTNBC)","publication_year":2019,"publication_date":"2019-03-01","ids":{"openalex":"https://openalex.org/W2942237342","mag":"2942237342"},"language":"en","primary_location":{"id":"mag:2942237342","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1193/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5006121692","display_name":"Lynda McGahan","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Lynda McGahan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5006121692"],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.04624603,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8984000086784363,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.8984000086784363,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.09719999879598618,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0013000000035390258,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9890000224113464},{"id":"https://openalex.org/keywords/nab-paclitaxel","display_name":"nab-paclitaxel","score":0.9919999837875366},{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":0.9549999833106995},{"id":"https://openalex.org/keywords/pd-l1-blockade","display_name":"PD-L1 blockade","score":0.800000011920929},{"id":"https://openalex.org/keywords/first-line-treatment","display_name":"first-line therapy","score":0.7509999871253967},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8529999852180481},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5249999761581421},{"id":"https://openalex.org/keywords/immune-related-adverse-events","display_name":"immune-related adverse events","score":0.6809999942779541},{"id":"https://openalex.org/keywords/neutropenia","display_name":"neutropenia","score":0.777999997138977},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.46399998664855957},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.828000009059906},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.7110000252723694},{"id":"https://openalex.org/keywords/tumor-infiltrating-immune-cells","display_name":"tumor-infiltrating immune cells","score":0.7680000066757202},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.5910000205039978}],"concepts":[{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.9882903695106506},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8075518012046814},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.6830695867538452},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.6197823286056519},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6110039353370667},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.5568764209747314},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.5479259490966797},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5452074408531189},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.5206419825553894},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.49644309282302856},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3878307342529297},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.35273224115371704},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3497161865234375},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.34492748975753784},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.13020071387290955},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2942237342","doi":null,"is_oa":false,"landing_page_url":"http://eprints.aihta.at/1193/","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3014206773","https://openalex.org/W4411036462","https://openalex.org/W4308252516","https://openalex.org/W2790744911","https://openalex.org/W2342693333","https://openalex.org/W2897422388","https://openalex.org/W3175173749","https://openalex.org/W4396587193","https://openalex.org/W3184991109","https://openalex.org/W3087393791"],"abstract_inverted_index":{"In":[0,136],"patients":[1,67,315],"with":[2,191,227,282,298],"triple":[3],"negative":[4],"breast":[5],"cancer":[6,24],"(TNBC),":[7],"overexpression":[8],"of":[9,43,96,110,126,145,159,201,257,264,308,336],"programmed":[10],"death":[11,129,162],"ligand":[12],"1":[13,81],"(PD-L1)":[14],"on":[15,79,90],"tumour-infiltrating":[16,293],"immune":[17,28,333],"cells":[18,25],"(IC)":[19],"increases":[20],"the":[21,41,58,108,124,137,143,157,194,205,255,275],"propensity":[22],"for":[23,248],"to":[26,36,49,71,133,166,212,243,313,330,345,351],"evade":[27],"surveillance.":[29],"Atezolizumab":[30,224],"(Tecentriq\u00ae),":[31],"a":[32,317],"monoclonal":[33],"antibody":[34],"designed":[35],"inhibit":[37],"PD-L1,":[38],"enables":[39],"both":[40],"activation":[42],"T-cells":[44],"and":[45,52,82,94,122,155,199,208,235,253,291,301,306,344],"restoring":[46],"their":[47],"ability":[48],"effectively":[50],"detect":[51],"destroy":[53],"tumour":[54,342],"cells.":[55],"During":[57],"phase":[59],"III,":[60],"IMpassion130":[61],"trial,":[62],"902":[63],"treatment-naive":[64],"advanced":[65,249],"TNBC":[66,250],"were":[68,177],"randomised":[69],"1:1":[70],"840":[72],"mg":[73],"atezolizumab":[74,106,141,192,242,265],"IV":[75,78,89],"or":[76,103,128,161,259],"placebo":[77,187],"days":[80,91],"15,":[83],"plus":[84],"100":[85],"mg/m2":[86],"nab-paclitaxel":[87,167,244],"(Abraxane\u00ae)":[88],"1,":[92],"8,":[93],"15":[95],"every":[97],"28-day":[98],"cycle,":[99],"until":[100],"disease":[101],"progression":[102,127,160,258],"toxicity.":[104,325],"Adding":[105],"increased":[107,142,193,299],"rate":[109,144,197],"progression-free":[111],"survival":[112,175],"(PFS)":[113],"by":[114,119,130,147,152,163],"6%,":[115],"prolonged":[116,149],"median":[117,150],"PFS":[118,146,151,252,262],"1.7":[120],"months,":[121,154,222],"reduced":[123,156],"risk":[125,158,256],"20%":[131],"compared":[132,165,211],"chemotherapy":[134,213,269],"alone.":[135,168],"PD-L1-positive":[138,209,276],"subgroup,":[139],"adding":[140,241],"13%,":[148],"2.5":[153],"38%":[164],"No":[169],"statistically":[170],"significant":[171],"differences":[172],"in":[173,204,274],"overall":[174],"(OS)":[176],"noted":[178],"between":[179],"groups":[180],"(21.3":[181],"months":[182,186,219],"atezolizumab-":[183],"versus":[184,216,220],"17.6":[185],"combination).":[188],"Combination":[189],"therapy":[190,247,267],"objective":[195],"response":[196,202],"(ORR)":[198],"duration":[200],"(DOR)":[203],"intention-to-treat":[206],"(ITT)":[207],"group":[210],"alone":[214,270],"(10%":[215],"16%;":[217],"1.8":[218],"3.0":[221],"respectively.":[223],"was":[225,271],"associated":[226,297],"neutropenia,":[228],"decreased":[229],"neutrophils,":[230],"peripheral":[231],"neuropathy,":[232],"fatigue,":[233],"anaemia":[234],"immune-mediated":[236],"adverse":[237],"events.":[238],"Overall,":[240],"as":[245],"first-line":[246,286],"prolongs":[251],"reduces":[254],"death.":[260],"The":[261],"benefit":[263,320],"combination":[266,338],"over":[268,321],"also":[272],"consistent":[273,281],"subgroup.":[277],"These":[278],"results":[279],"are":[280,295,311,328],"previous":[283],"reports":[284],"suggesting":[285],"atezolizumab,":[287],"PD-L1":[288],"expression":[289],"\u22651,":[290],">10%":[292],"IC":[294],"independently":[296],"ORR":[300],"PFS.":[302],"Mature":[303],"OS":[304],"data":[305],"quality":[307],"life":[309],"measures":[310],"needed":[312,329],"ensure":[314],"achieve":[316],"clinically":[318],"relevant":[319],"time":[322],"despite":[323],"manageable":[324],"Further":[326],"studies":[327],"identify":[331],"predictive":[332],"biomarkers":[334],"selective":[335],"responders,":[337],"strategies":[339],"that":[340],"enhance":[341],"immunogenicity,":[343],"determine":[346],"whether":[347],"these":[348],"findings":[349],"extend":[350],"other":[352],"chemoimmunotherapy":[353],"combinations.":[354]},"counts_by_year":[],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2019-05-03T00:00:00"}